SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics announced FDA acceptance of its resubmitted…

Outlook Therapeutics, Inc. · 8-K filed Jun 16, 2026 at 08:46 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 16, 2026 at 08:46 ET

Outlook Therapeutics announced FDA acceptance of its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) to treat wet AMD. The FDA classified the resubmission as a Class 1 review with a 60-day review period, setting a PDUFA goal date of July 29, 2026. This moves the company one step closer to potential U.S. approval for its ophthalmic bevacizumab formulation, which already has marketing authorization in the EU and UK.

  • FDA accepted resubmitted BLA for ONS-5010 (bevacizumab-vikg) for wet AMD
  • Class 1 review with 60-day review period
  • PDUFA goal date set for July 29, 2026
  • ONS-5010/LYTENAVA already approved in EU and UK for wet AMD

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access